Egle Therapeutics to share preclinical data for its first autoimmune disease program, EGL-003, with an oral presentation at the 2024 Promise of Interleukin-2 Therapy Meeting
17 Julio 2024 - 11:00AM
Business Wire
Egle Therapeutics, a biotechnology company focused on advancing
the next generation of regulatory T cell-focused therapies for
oncology and auto-immunity, will deliver an oral presentation at
The Promise of Interleukin-2 Therapy meeting taking place in Paris
from September 4th to 7th, 2024.
The presentation, entitled “EGL-003, a novel IL-2 mutein to
selectively expand and activate regulatory T cells and improve
therapeutic efficacy in autoimmune disease”, will show evidence
that EGL-003, a non-targeted Fc-fused IL-2 agonist mutein,
selectively binds to regulatory T cells (Treg) and induces Treg
IL-2 signaling.
The resulting increase of Treg frequencies was observed in vitro
and in different mouse models. Accordingly, EGL-003 significantly
improved clinical, macroscopic, and histological parameters in a
DSS-induced colitis mouse model with expansion of tissue-resident
Tregs.
EGL-003 is the first drug candidate being developed for
treatment of autoimmune diseases in Egle’s pipeline and has
advanced into IND-enabling studies.
Session Title: IL-2 and Treg cell therapies; Session
Date and Time: Friday September 6th, 2024 2:00 PM - 3:30 PM;
Location: Poster Section 4; Poster Board Number: 23
Published Abstract Number: 4079
About Egle Therapeutics SAS (Egle)
Egle Therapeutics is a biotechnology company focused on
developing immunotherapies targeting suppressive regulatory T
cells. Egle is leveraging a proprietary discovery platform to
unveil novel Treg specific targets and to develop innovative
Treg-focused drug candidates for oncology and autoimmune diseases.
Egle aspires to advance toward the clinic its most advanced drug
candidates, EGL-001 (a Treg-selective anti-CTLA4-IL-2m) and EGL-003
(non-targeted IL-2 Treg engager), which are currently in
IND-enabling studies.
Find out more at www.egle-tx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240717654160/en/
contact@egle-tx.com / 0033 (0)1 86 64 08 57
investor.relations@egle-tx.com / 0033 (0)1 86 64 08 57